Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2131929 | 1.00 | ALDH1A1 (0.30) | ALDH1A1PKM | |
| SCHEMBL3510269 | 0.74 | — | — | |
| SCHEMBL8903859 | 0.59 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL31694898 | 0.58 | ALDH1A1 (0.44) | ALDH1A1 | |
| SCHEMBL8903780 | 0.57 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL25431983 | 0.53 | — | — | |
| SCHEMBL8169600 | 0.53 | — | — | |
| SCHEMBL9665669 | 0.53 | — | — | |
| SCHEMBL350336 | 0.53 | FFAR3 (0.47) | — | |
| SCHEMBL911085 | 0.53 | FFAR3 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 572 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124274-A1 | METHODS OF INCREASING READTHROUGH OF A PREMATURE TERMINATION CODON | UNIV RAMOT (IL) | 2026-05-07 | — | — | US | claimed |
| EP-4712983-A1 | AGENTS TO GENERATE REPAIR OLIGODENDROCYTES AND THEIR USE FOR AXONAL REGROWTH | Johannes Gutenberg-Universität Mainz (DE) | 2026-03-25 | — | — | EP | claimed |
| US-20260027096-A1 | PHD INHIBITORS | UNIV OXFORD INNOVATION LTD (GB) | 2026-01-29 | — | — | US | claimed |
| EP-4661861-A1 | USE OF HIF-1A STABILIZING AGENTS FOR THE TREATMENT OF TYPE I INTERFERONOPATHIES | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-12-17 | — | — | EP | claimed |
| EP-4655288-A1 | PHD INHIBITORS | Oxford University Innovation Limited (GB) | 2025-12-03 | — | — | EP | claimed |
| WO-2025120597-A1 | SECRETOME-BASED BIOMATERIAL, METHOD FOR ITS PRODUCTION AND USES THEREOF | UNIVERSIDADE DE AVEIRO (PT) | 2025-06-12 | — | — | WO | claimed |
| US-12319740-B2 | Methods for production of tissue resident memory-like T cells and use thereof | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-06-03 | — | — | US | claimed |
| US-20250129170-A1 | EPO RECEPTOR AGONISTS AND ANTAGONISTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2025-04-24 | — | — | US | claimed |
| CN-119700682-A | Polycyclodextrin/dimethoxyoxalylglycine composite nano-particle, and preparation method and application thereof | 山东大学 | 2025-03-28 | — | — | CN | claimed |
| CN-119546750-A | Methods for making and using differentiated neural cells | 研究发展基金会 | 2025-02-28 | — | — | CN | claimed |
| WO-2008157177-A1 | METHODS FOR MODULATING OSTEOBLAST CELL DIFFERENTIATION AND BONE GENERATION THROUGH INHIBITION OF A PROLYL HYDROXYLASE | THE UAB RESEARCH FOUNDATION (US) | 2008-12-24 | — | — | WO | claimed |
| EP-1912637-A2 | INHIBITORS OF EGLN3 ACTIVITY FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2008-04-23 | — | — | EP | claimed |
| WO-2007009044-A2 | INHIBITORS OF EGLN3 ACTIVITY FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | DANA FARBER CANCER INSTITUTE, INC. (US) | 2007-01-18 | — | — | WO | claimed |
| EP-1451341-A4 | EIT-6, A POLYPEPTIDE ENCODED BY AN ESTROGEN REGULATED GENE | DANA FARBER CANCER INST INC (US) | 2005-07-13 | — | — | EP | claimed |
| US-20040248139-A1 | Eit-6, a polypeptide encoded by an estrogen regulated gene | DANA-FARBER CANCER INSTITUTE, INC. | 2004-12-09 | — | — | US | claimed |
| EP-1451341-A2 | EIT-6, A POLYPEPTIDE ENCODED BY AN ESTROGEN REGULATED GENE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2004-09-01 | — | — | EP | claimed |
| US-20040146964-A1 | hydroxylases which act on hypoxia inducible factor alpha (HIF- alpha ) and which are involved in the regulation of the cellular turnover of HIF | ISIS INNOVATION LIMITED (GB) | 2004-07-29 | — | — | US | claimed |
| EP-1379630-A2 | ASSAYS, METHODS AND MEANS RELATING TO HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE | ISIS INNOVATION LIMITED (GB) | 2004-01-14 | — | — | EP | claimed |
| WO-2003042363-A2 | EIT-6, A POLYPEPTIDE ENCODED BY AN ESTROGEN REGULATED GENE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2003-05-22 | — | — | WO | claimed |
| WO-2002074981-A2 | ASSAYS, METHODS AND MEANS RELATING TO HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE | ISIS INNOVATION LTD. (GB) | 2002-09-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124274-A1 | METHODS OF INCREASING READTHROUGH OF A PREMATURE TERMINATION CODON | RNMT, TRMT1L, UPF1 | ALDH1A1 4769/4885PKM 2276/4885 |
| US-20250129170-A1 | EPO RECEPTOR AGONISTS AND ANTAGONISTS | EPOR, MPL, PRLHR | ALDH1A1 3118/4885PKM 4102/4885 |
| US-20260027096-A1 | PHD INHIBITORS | HIF1AN, HIF1A, EGLN1 | ALDH1A1 113/4885PKM 2217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.